Luseogliflozin Suppresses Fine Glycemic Fluctuation Late at Night: New Aspect of SGLT2 Inhibitor

被引：0
|
作者：
Yamauchi, Keishi
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-798-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] LUSEOGLIFLOZIN SGLT2 Inhibitor Treatment of Diabetes
    Tiwari, A.
    DRUGS OF THE FUTURE, 2012, 37 (09) : 637 - 643
  • [2] SGLT2 Inhibitor Luseogliflozin Improves Nonalcoholic Hepatosteatosis in a Rodent Model
    Fujishiro, Midori
    Nakatsu, Yusuke
    Sakoda, Hideyuki
    Kushiyama, Akifumi
    Asano, Tomoichiro
    DIABETES, 2015, 64 : A721 - A721
  • [3] SGLT2 Inhibitor, Luseogliflozin, Prevent Sarcopenia by Improving Extracellular Lipidome
    Bamba, Ryo
    Okamura, Takuro
    Hashimoto, Yoshitaka
    Senmaru, Takafumi
    Hamaguchi, Masahide
    Fukui, Michiaki
    DIABETES, 2021, 70
  • [4] Effects of a Novel SGLT2 Inhibitor Luseogliflozin on Intravaginal Bacteria and Fungi
    Kusunoki, Masataka
    Natsume, Yukie
    Sato, Daisuke
    Yamagishi, Yuka
    Suematsu, Hiroyuki
    Tsutsui, Hideyo
    Oshida, Yoshiharu
    Nakamura, Takao
    Mikamo, Hiroshige
    DIABETES, 2015, 64 : A331 - A331
  • [5] Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
    Kojima, Naoki
    Williams, Jan M.
    Takahashi, Teisuke
    Miyata, Noriyuki
    Roman, Richard J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (03): : 464 - 472
  • [6] Enhancement of Flattening Glycemic Fluctuation in Patients with Type 2 Diabetes by SGLT2 Inhibitor Combined with DPP-4 Inhibitor
    Cho, Kyuyong
    Nomoto, Hiroshi
    Nakamura, Akinobu
    Omori, Kazuno
    Atsumi, Tatsuya
    Miyoshi, Hideaki
    DIABETES, 2019, 68
  • [7] Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study
    Samukawa, Yoshishige
    Sata, Michio
    Furihata, Kenichi
    Ito, Toshifumi
    Ueda, Naohiko
    Ochiai, Hidekazu
    Sakai, Soichi
    Kumagai, Yuji
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (05): : 439 - 447
  • [8] Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    Shirong Qiang
    Yusuke Nakatsu
    Yasuyuki Seno
    Midori Fujishiro
    Hideyuki Sakoda
    Akifumi Kushiyama
    Keiichi Mori
    Yasuka Matsunaga
    Takeshi Yamamotoya
    Hideaki Kamata
    Tomoichiro Asano
    Diabetology & Metabolic Syndrome, 7
  • [9] Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    Qiang, Shirong
    Nakatsu, Yusuke
    Seno, Yasuyuki
    Fujishiro, Midori
    Sakoda, Hideyuki
    Kushiyama, Akifumi
    Mori, Keiichi
    Matsunaga, Yasuka
    Yamamotoya, Takeshi
    Kamata, Hideaki
    Asano, Tomoichiro
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [10] Long-term Efficacy and Safety of Luseogliflozin, an SGLT2 inhibitor, in Elderly Patients with Type 2 Diabetes
    Sasaki, Takashi
    Seino, Yutaka
    Haneda, Masakazu
    Inagaki, Nobuya
    Fukatsu, Atsushi
    Ubukata, Michito
    Sakai, Soichi
    Samukawa, Yoshishige
    DIABETES, 2014, 63 : A275 - A275
12345